HC Wainwright Issues Negative Estimate for Alkermes Earnings

Alkermes plc (NASDAQ:ALKS) – Equities research analysts at HC Wainwright reduced their Q1 2025 earnings per share (EPS) estimates for shares of Alkermes in a report issued on Thursday, February 13th. HC Wainwright analyst D. Tsao now anticipates that the company will earn $0.22 per share for the quarter, down from their previous forecast of $0.27. HC Wainwright currently has a “Neutral” rating and a $46.00 price target on the stock. The consensus estimate for Alkermes’ current full-year earnings is $2.23 per share. HC Wainwright also issued estimates for Alkermes’ Q2 2025 earnings at $0.31 EPS and Q4 2025 earnings at $0.39 EPS.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 22.15% and a return on equity of 24.92%.

Several other brokerages also recently issued reports on ALKS. Piper Sandler reiterated an “overweight” rating and set a $37.00 price target (down from $38.00) on shares of Alkermes in a report on Friday, October 25th. The Goldman Sachs Group boosted their price objective on shares of Alkermes from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. StockNews.com raised Alkermes from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 13th. Mizuho raised their price objective on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Alkermes in a research note on Tuesday, February 11th. They issued a “buy” rating and a $40.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Alkermes has a consensus rating of “Moderate Buy” and an average target price of $37.25.

Alkermes Price Performance

ALKS stock opened at $35.94 on Monday. Alkermes has a 1 year low of $22.90 and a 1 year high of $36.45. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.45 and a quick ratio of 3.03. The stock has a market cap of $5.84 billion, a price-to-earnings ratio of 18.43, a P/E/G ratio of 1.83 and a beta of 0.49. The company has a 50 day simple moving average of $30.49 and a 200 day simple moving average of $28.87.

Insider Activity

In related news, EVP Craig C. Hopkinson sold 144,419 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $35.53, for a total value of $5,131,207.07. Following the transaction, the executive vice president now directly owns 57,875 shares in the company, valued at $2,056,298.75. This trade represents a 71.39 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Cato T. Laurencin sold 2,691 shares of the business’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $31.85, for a total transaction of $85,708.35. Following the sale, the director now directly owns 23,013 shares of the company’s stock, valued at approximately $732,964.05. The trade was a 10.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 323,608 shares of company stock worth $10,854,725 in the last quarter. 4.89% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Alkermes

Institutional investors and hedge funds have recently bought and sold shares of the stock. Centiva Capital LP bought a new stake in shares of Alkermes in the 3rd quarter worth $367,000. Natixis Advisors LLC increased its stake in Alkermes by 190.3% in the 3rd quarter. Natixis Advisors LLC now owns 36,490 shares of the company’s stock valued at $1,021,000 after buying an additional 23,921 shares during the last quarter. Vontobel Holding Ltd. lifted its holdings in Alkermes by 128.9% during the third quarter. Vontobel Holding Ltd. now owns 56,261 shares of the company’s stock worth $1,575,000 after acquiring an additional 31,687 shares during the period. Sanctuary Advisors LLC boosted its holdings in shares of Alkermes by 254.5% in the 3rd quarter. Sanctuary Advisors LLC now owns 32,791 shares of the company’s stock worth $944,000 after buying an additional 23,541 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Alkermes by 74.7% in the third quarter. BNP Paribas Financial Markets now owns 149,493 shares of the company’s stock valued at $4,184,000 after acquiring an additional 63,939 shares during the last quarter. 95.21% of the stock is owned by hedge funds and other institutional investors.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.